Synapse - Department of Medicine

Results (39711)

Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy

Meeting Abstract

Blinder, V. S.; Finik, J.; Patil, S.; Narang, B.; Claros, M.; Suarez, J.; Martinez, S.; Muppidi, M.; Makower, D. F.; Gillis, T.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study

Meeting Abstract

Mooghali, M.; Wallach, J. D; Mitchell, A. P.; Skydel, J. J.; Ross, J. S.; Ramachandran, R.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Quantifying the growth of clinical actionability in precision oncology using OncoKB

Meeting Abstract

Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition

Meeting Abstract

Daly, R. M.; Brawley, O. W.; Gospodarowicz, M. K.; Olopade, O. I.; Fashoyin, I.; Wolodzko Smart, V.; Chang, I. F.; Tendler, C. L.; Kim, G.; Fuchs, C. S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer

Meeting Abstract

Mukherjee, S.; Schroeder, A.; Chatterjee, S.; Cadley, J.; Falcon, C. J.; Mehine, M.; Bandlamudi, C.; Chatterjee, A.; Ladanyi, M.; Solit, D. B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

Meeting Abstract

Chia, S.; Neven, P.; Ciruelos, E. M.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Prat, A.; Park, Y. H.; Juric, D.; Turner, N. C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment

Meeting Abstract

Wander, S. A.; Weipert, C. M.; Liao, J.; Safonov, A.; Zhang, N.; Bardia, A.; Razavi, P.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer

Meeting Abstract

Rosen, E.; Sharma, M.; Berz, D.; Caswell-Jin, J. L.; Spira, A. I.; Fulgar, G. A.; Densel, M.; Rana, N.; Sperry, S.; Warner, D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04

Meeting Abstract

Modi, S.; Niikura, N.; Yamashita, T.; Jacot, W.; Sohn, J.; Tokunaga, E.; Vidal, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial

Meeting Abstract

Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Iwata, H.; Jhaveri, K. L.; Loibl, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save